STAAR Surgical Company (STAA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on January 14, 2026, with the report filed on January 15, 2026. The filing details a material definitive agreement with Broadwood Partners, L.P., resulting in significant changes to the Company's Board of Directors and executive leadership.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes and executive compensation arrangements.
Material Changes and Leadership Transition
- Board Composition: The Board size increased from six to seven directors. Stephen C. Farrell and Elizabeth Yeu, MD resigned. Neal C. Bradsher, Richard T. LeBuhn, and Christopher Min Fang Wang were appointed as new directors.
- CEO Departure: Stephen C. Farrell stepped down as a Board member effective January 14, 2026. His employment as Chief Executive Officer terminates on January 31, 2026, or earlier at the Board's discretion.
- Executive Compensation: Mr. Farrell's departure is treated as a termination without cause. He is eligible for 18 months of base salary and 18 months of insurance premium reimbursement, subject to a general release. He will also receive consulting fees of $45,000 per month for one year post-separation.
- Equity Vesting: Mr. Farrell's unvested RSUs will continue to vest during the consulting period, except for those scheduled for February 2026 (which will vest on schedule) and others (which will be forfeited). Performance-based RSUs are capped at 140,100 units, contingent on goals through July 3, 2026.
Outlook, Risks, and Contingencies
- NASDAQ Compliance Risk: Due to Dr. Yeu's resignation, the Audit Committee temporarily fell below the required three independent directors under NASDAQ Listing Rule 5605. The Company notified NASDAQ of noncompliance and intends to use the cure period to regain compliance.
- Shareholder Meeting Restriction: Broadwood Partners agreed not to request a special meeting of stockholders until June 18, 2026.
- Expense Reimbursement: The Company agreed to reimburse Broadwood, Yunqi Capital, and Defender Capital for reasonable out-of-pocket fees and expenses.
Investor Verification Checklist
- Verify the exact date of Stephen C. Farrell's final departure as CEO (January 31, 2026 or earlier).
- Confirm the timeline for appointing a new independent director to restore full NASDAQ Audit Committee compliance.
- Review the full text of the Cooperation Agreement (Exhibit 10.1) for additional covenants or conditions.
- Monitor the Company's announcement regarding the appointment of a permanent CEO to succeed Mr. Farrell.